CAMBRIDGE

Cambridge University Press
978-0-521-81097-5 — Epidemiological Studies
Alan J. Silman, Gary J. Macfarlane
Index
More Information

Index

Numbers in italics indicate *tables* or *figures*.

age, effects on disease occurrence 4–5
age-restricted populations *54*
age-specific rates 25–8, 163, *165*
age-standardised rates 21–4, 164–7, 197–9
agreement assessment *see* observers: agreement assessment
antipathy to research 132
archived data 157
association
  measures 45
    attributable risks 48–9
    odds ratios *see* odds ratio calculation
    precision 49
    rate ratios 46–7, 179–81
    risk ratios 45–6, 181–2, 194, *196*
  term 5
attributable risks 48–9, *180*

back pain *36*
bias 201
  defined 201
  direction of 202
  effects on validity 203
  feasibility of unbiased studies 212
  information bias
    observer 122, 125, 209–10
    subject (recall) 210–11
  non-directional misclassification 202–3
  selection bias
    non-response 205–8
    of participants 204–5
    special situations 208–9
birth-cohort effects 26, *28*
breast cancer 34
buddy controls 86–7

case-control studies 37–9
  bias 201, 206
  matching 88
    frequency 89–90
    individual 88–9
    to minimise confounding 88, 190–1
  nested 40, 41, 43
  odds ratios *see* odds ratio calcuation
  study size 90–2
  subject selection *see* subject selection for case-control studies
  see also study types: choice
cases
  ascertainment 65–6
  selection *see* subject selection for case-control studies: cases
  verification 66, 78, 79–81
catchment population methods 55
  accuracy of population data 56–7
  incidence measurement
    definition of cases 65–6
    prospective notification 63, 64–5, 66
    retrospective review 63–4
    suitability of approach 60, 61, *62*
  prevalence measurement 69–70
census data 53, 55, 56
chi-square (χ^2) 172–3, 175, 176
clinical epidemiology 6
clinical trials 6
  see also study types
closed questions 106–8
cluster (multistage) sampling 59
cohort effects 26
cohort studies 39–41
  analysis 179–87
  bias 201, 205
  follow-up *see* follow-up of study cohorts
  multiple exposure effects 96
  prospective 39, 40, *41*, 42, 43, 44
  retrospective 39, 40, 42, 43
  study size 97–9
  subject selection *see* subject selection for cohort studies
  see also study types: choice
commercial mailing lists 56
computer programs 90, 146, 169

© in this web service Cambridge University Press www.cambridge.org

CAMBRIDGE

Cambridge University Press
978-0-521-81097-5 — Epidemiological Studies
Alan J. Silman, Gary J. Macfarlane
Index
More Information

computer use
  data analysis 169
  data preparation 145, 146
conditional logistic regression 178
confidence intervals 49, 170
  incidence rates 159–60, *161*
  incidence rate ratios 180–1
  odds ratios
    matched pair analysis 178
    'test'-based method 172–3
    Woolf's method 173–4
  prevalence proportions 161–2
  risk ratios 182
confidentiality *see* ethical issues: confidentiality of data
confounding 9, 188–90
  analysis of
    baseline comparisons 192–3
    multivariate techniques 199–200
    standardisation 197–9
    stratification 193–7
  in ecologic studies 32
  minimisation in study design 190
    matching 88, 190–1
    unknown confounders 89, 191
  monitoring studies for 191–2
  negative 189
consent 225–7
continuous exposures 49, *50*
control selection *see* subject selection for case-control studies: controls
correlation studies 31–3
costs
  costing a study 229
    flowchart *230*
    personal time 231–3
  reduction 233–4
    personal costs 234
    postage/printing 235
  reimbursement of subjects 131
  and study design 42, 228–9
  of wastage 235–6
cotinine 118
Cox's (proportional hazards) regression 200
cross-sectional studies 35–7
  analysis 169
  bias 201, 206
  incidence measurement 67–8
  see also study types: choice
crude rates of disease 163
cumulative incidence 15, 16, *18*, 160–2, 181–2
cumulative prevalence 17, *18*, 160–2
cut-off assignment 113–15

data
  accuarcy 56–7
  analysis 168–9, 170
    case-control studies *see* odds ratio calculation
    cohort studies 179–87
    resource wastage on 236
    statistical packages 169
  collection 39, 103 *see also* questionnaires
  consistency checks *152*, 153, 154
  interpretation *8*, 9
  missing 155–6
  preparation for analysis 145, 146, 147
    costs 231, 232, 233, 234
    initial checking 147–9
    linkage from multiple sources 149
    data coding schedule development 149–51
    database development 151–3
    data entry 153–4
    checking entered data 154
    consideration of missing data 155–6
    recoding entered data 156–7
    storage 157
    use of computers 145, 146
  protection 218
  qualtiy 8–9, 56–7
  range checks 152, 154
  repeatability 9, 120
    analysis of 123–7
    observer bias 122, 125
    observer consistency 121–2, 140–1
    studies to measure 122–3
  storage 157
  validity 9, 111
    bias and 203
    misclassification 116, 118–19
    non-dichotomous variables 115–16
    sensitivity and specificity 112–15
    validation approaches 116–18
database packages 146, 169
databases 77–8
  in-built checks 152–3
  subject identification numbers 152
dichotomous exposures 49, *50*, 115, 171
disease causation studies *4*, 5
disease controls 85–6
disease definitions 3–4
disease management *4*, 6
disease occurrence 4–5
  measures 13
    choice 17–19
    incidence *see* incidence
    prevalence *see* prevalence
  population selection for studies *see* population selection
  rate comparisons 20–1
    age-specific 25–8
    over time 24–5
    standardisation methods *see* standardisation
disease outcome *4*, 5–6, 40
disease prevention *4*, 6
distress in study participants 224–5
double data entry 153

© in this web service Cambridge University Press www.cambridge.org

CAMBRIDGE

Cambridge University Press
978-0-521-81097-5 — Epidemiological Studies
Alan J. Silman, Gary J. Macfarlane
Index
More Information

ecologic fallacy 33
ecologic studies 31–3, 42
electoral registers 56, 84
environmental factors in disease, migrant studies 33–4
EPI INFO package 90
epidemiology
  analytical 168–87
  clinical 6
  defined 3
  descriptive 158–67
  ethical issues 215–27
  population 6
  research issues 7–9
  scope 3–6
episode incidence 15, *18*
ethical issues 215
  confidentiality of data
    collected for the study 219–20
    from third parties 220–1
  consent 225–7
  data protection 218
  detection of previously unrecognised disease 221
    not requiring intervention 222–3
    requiring intervention 223–4
    unrelated to the study 224
  distress among participants 224–5
  ethical approval 215–16
  in maximisation of response rate 216–17
  opt out or opt in 217
  scientific validity 216
exposure categorisation 49–50, 95–7
external validity of studies 203

family controls 86–7
feasibility of studies 41
first-ever incidence 14–15, *18*
follow-up of study cohorts 39–40, 184
  losses and life table use 184
  participation 132–3
    disease status ascertainment 133–5
    loss minimisation 135–7
  sample size and 99
frequently matching 89–90
friend controls 86–7

general practice registers 55–6, 134
generalisability of results 9
genetic factors in disease, migrant studies 34
geographical/geopolitical populations 53, *54*

hazard ratios 183
health service delivery 6
home visits 130, 217

identification numbers 152, 219, 220
incidence 13
  cumulative 15, 16, *18*
  episode 15, *18*
  first-ever 14–15, *18*
  life-table analysis 182–5
  measurement
    approaches summarised 60–3
    catchment population methods *see* catchment population methods: incidence measurement
    indirect 71–3
    population surveys 67–8
  rates (densities) 13–14, 158–9
    confidence intervals 159–60, *161*, 180–1
    ratios 46–7, 179, 180–1
incidence/prevalence bias 205
individual matching 88–9
information *see* data
information bias 209–11
inner-city populations 57
internal validity of studies 203
interpretation of results *8*, 9
intervention studies 6
interview-administered questionnaires *see* questionnaires: interview-administered
interviewers 105, 148
  see also observers

Kaplan–Meier curves 185
kappa (κ) statistic 123–6

Latin square design 122–3
left censorship 68
life-table method 182–5, 200
lifestyle factors in disease, migrant studies 34
linear trend determination 175–7
logistic regression 171, 178, 199–200
LogRank test 185–7
longitudinal studies *see* cohort studies
lung cancer, age-specific mortality rates 26, *27*, *28*

Mantel–Haenszel estimates 194–5
measures of association *see* association: measures
measures of disease occurrence *see* disease occurrence: measures
medical record access 220–1, *222*
melanoma skin cancer 31, *32*
migrant studies 33–5, 42
misclassification of subjects 116, 118–19
multistage (cluster) sampling 59

National Health Service Central Register 221
national surveys 54
neighbour controls 85
nested case-control studies 40, 41, 43
new incidence 14–15, *18*
non-response bias 205–8

observers
  agreement assessment 122
    for categorical measures 123–6

© in this web service Cambridge University Press www.cambridge.org

CAMBRIDGE

Cambridge University Press
978-0-521-81097-5 — Epidemiological Studies
Alan J. Silman, Gary J. Macfarlane
Index
More Information

observers (*cont.*)
for continuous measures 126–7
kappa statistic 123–6
study designs for 122–3
bias 122, 125, 209–10
consistency 121–2, 140–1
see also interviewers
occurrence of disease *see* disease occurrence
odds ratio calculation 47–8, 171–2
confidence intervals *see* confidence intervals: odds ratios
dichotomous exposures 171
Mantel–Haenszel estimates 194–5
matched pairs 177–8
multiple exposure levels 174–5
Office for National Statistics 221
open questions 106–8
optical scanning of questionnaires 154, 234
overmatched cases and controls 87, 89

p values 170
participation
bias 204–5
ethical constraints in maximisation 216–17
in follow-up *see* follow-up of study cohorts: participation
pilot studies to estimate 139
reasons for non-participation 128
antipathy to research 132
anxiety about health 131
avoidance of discomfort 131
cost 131
inconvenience 129–30
lack of interest 129
period prevalence 17, *18*, 35
person–years 14
personnel costs 231–3, 234
pilot studies 138–41
point prevalence 17, *18*, 35
Poisson distribution 159
Poisson regression 200
population attributable risk 48, 180
population registers 55–6, 82, 84
population sampling 57–9
population selection
criteria
access 55–6
data accuracy 56–7
representativeness 54–5
study size 57–9
population groups 53–4
problems 7–8
see also subject selection for case-control studies; subject selection for cohort studies
population surveys 55
costing model 229–33
data accuracy 57
incidence measurement
left censorship 68
single or duplicate surveys, *62*, 67–8
prevalence measurement 70–1
sample size requirements *58*
populations
age-restricted *54*
free-living 7, 33
geographical/geopolitical 53, *54*
inner-city 57
reference 164
standard 21–2, 164–5
world standard 22, *23*
postal surveys 71
mining inconvenience 130
strategy following poor response 217
prevalence 16
cumulative 17, *18*, 160–2
measurement
approaches 68
catchment population methods 69–70
indirect 72
population surveys 70–1
period 17, *18*, 35
point 17, *18*, 35
proportions 16, 160
confidence intervals 161–2
risk ration estimation from 181–2
prospective cohort studies *see* cohort studies: prospective
proxy respondents 37, 76, 103

questionnaires
confidentiality 219–20
formulation 106
design 108–10
open and closed questions 106–8
front sheets 219
interview-administered
by telephone 106
compared with self-completed 103–5
data checking 148
immediate data entry 153–4
missing data 155
pilot-testing 139–40
pre-coded *147*, 150
resource wastage on 235–6
self-completed
compared with interview-administered 103–5
data checking 147–8

ranked exposures 49, *50*
rare diseases
retrospective studies 65
subject recruitment 78, 79
rate comparisons *see* disease occurrence: rate comparisons
rate difference 48, 179, 180
rate ratios 46–7, 179–81

© in this web service Cambridge University Press www.cambridge.org

CAMBRIDGE

Cambridge University Press
978-0-521-81097-5 — Epidemiological Studies
Alan J. Silman, Gary J. Macfarlane
Index
More Information

rates
  age-specific 25–8, 163, *165*
  age-standardised 21–4, 164–7, 197–9
  crude 163
  incidence *see* incidence: rates (densities)
  prevalence *see* prevalence: proportions
recall bias 210–11
recall by subjects 38, 105, 107
receiver operating characteristic (ROC) curves 113, *114*
registers 133
  electoral 56, 84
  general practice 55–6, 134
  linked 134
  National Health Service Central Register 221
  population 55–6, 82, 84
reliability 120
repeatability *see* data: repeatability
retrospective studies 63–4, 69
  case-control 43, 44
  cohort *see* cohort studies: retrospective
right censorship 184
risk difference (attributable risk) 48, *180*
risk ratios 45-6, 181–2, 194, *196*
risks 5, 15
  attributable 48–9, *180*
  relative 45–7 *see also* rate ratios; risk ratios
ROC (receiver operating characteristic) curves 113, *114*
Rochester Epidemiology Project 63
Rose Angina Questionnaire 111

sample size 57, *58*
  case-control studies 90–2
  cohort studies 97–9
  pilot study estimation 141
sample surveys of non-responders 208
sampling from populations 57–9
sampling units/frames 57, 82
selection bias *see* bias: selection bias
self-completed questionnaires 103–5, 147–8, 155
self-reported diagnosis *80*, 81
sensitivity 112–15
seven-day weighed-diet surveys 118
sex, effects on disease occurrence 4–5
simple random sampling 58
SIRs (standardised incidence ratios) 23, 164
specificity 112–15
standardisation 21
  analysis of confounding by 197–9
  direct 21–2, 164, *166*
  indirect 22–4, 164–5, *166–7*
standardised incidence ratios (SIRs) 23, 164
statistical packages 169
stomach cancer 38
stratification of confounders 193–7
stratified random sampling 58–9
study instruments *see* questionnaires
study samples 58
study size *see* sample size
study types 31
  case-control *see* case control studies
  choice 41–4
  cohort *see* cohort studies
  cross-sectional *see* cross-sectional studies
  ecologic (correlation) 31–3, 42
  migrant 33–5, 42
subject
  identification numbers 152, 219, 220
  misclassification 116, 118–19
  participation *see* participation
  variation 120
subject (recall) bias 210–11
subject selection for case-control studies
  cases
    diagnosed cases 77–8, 79
    exclusion criteria 81–2
    hospital-based series 77
    incident vs. prevalent cases 74, 75
    issues 74
    patient registration form *80*
    pilot studies for recruitment rate estimation 139
    population-based series 76–7
    strategies *75*
    verification of cases 78, 79–81
  controls 82
    disease controls 85–6
    family/friend controls 86–7
    ideal options *83*
    population-based selection 82, 84–5
    two groups 87–8
  sample size 90–2
  see also case-control studies: matching
subject selection for cohort studies 93
  exposure categorisation 95–7
  prospective cohorts 94–5
  retrospective cohorts 93–4
  sample size 97–9
subject–observer interactions 121
survey centre visits 130
survival curves 184–7
systematic sampling 58

telephone interviews 106
telephone recruitment of controls 84–5
test cut-off assignment 113-15
time-period effects 26
tracing individuals 137

urine cotinine 118

validity *see* data: validity

waste of resources 235–6
world standard population 22, *23*
written consent 225

© in this web service Cambridge University Press www.cambridge.org